Longeveron Inc. (NASDAQ: LGVN) issued a letter to stockholders outlining the company's strategic repositioning toward licensing partnerships and capital efficiency for its stem cell therapy laromestrocel.

Chief Executive Officer Stephen Willard, who joined in February, detailed the company's transition to a partnership-focused model following a comprehensive review of assets and development programs. The biotechnology company secured investment from Coastlands Capital, Janus Henderson Investors, Logos Capital and Kalehua Capital.

The company expects top-line data from its Phase 2b clinical trial (ELPIS II) in Hypoplastic Left Heart Syndrome in August 2026. HLHS is a rare pediatric congenital heart condition with no approved drug therapies. The program has received FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations.

Longeveron completed a financing transaction in March 2026 for up to approximately $30 million in gross proceeds, with $15 million received upfront and additional funding contingent on trial results and share price milestones. The company agreed to sell investors a 50% interest in proceeds from a potential Priority Review Voucher sale.

The company's laromestrocel therapy is supported by 52 issued patents worldwide and targets multiple indications including HLHS, Pediatric Dilated Cardiomyopathy, Alzheimer's disease, and aging-related frailty. The FDA accepted an Investigational New Drug application for PDCM, allowing the company to proceed directly to a Phase 2 registrational trial anticipated to begin in 2027.

For Alzheimer's disease, the company achieved FDA alignment on a single Phase 2/3 adaptive trial design. Results from a Phase 2a trial were published in Nature Medicine, showing statistically significant reductions in brain volume loss.